PROYECTO DE INVESTIGACIÓN

NOTCH PATHWAY IN CIRCULATING MYELOID-DERIVED SUPPRESSOR CELLS (MDSCS) AS PREDICTIVE BIOMARKERS OF RESPONSE TO IMMUNE CHECKPOINT INHIBITORS (CPIS) IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER (TNBC)

 

Objectives:
• Characterization of Notch ligands (Delta-like and Jagged) and receptor expression levels in Circulating
MDSCs in liquid biopsy prior to treatment initiation, at time of first radiologic evaluation and at
treatment discontinuation.
• Correlation of Notch ligands (Delta-like and Jagged) and receptors expression levels in Circulating
MDSCs at baseline with the objective response rate achieved with a front-line regimen including an
ICI (pembrolizumab, atezolizumab, or other) for locally advanced and/or metastatic TNBC.

 

Research team:
• José García Sánchez MD (Hospital Arnau de Vilanova)
• Sara Marín MD (Hospital Arnau de Vilanova)
• María Leonor Fernández-Murga PhD (Hospital Arnau de Vilanova)
• Lucía Serrano (Pre-doctoral student) (Hospital Arnau de Vilanova)
• Enrique O’Connor PhD (Universidad de Valencia)
• María Portero (Nurse) (Hospital Arnau de Vilanova)